Rahul Kumar, Medical Oncology Trainee at AIIMS, New Delhi, shared a post on X about a paper by Jakub Svoboda et al. published in NEJM:
“Promising for lymphoma patients who’ve failed prior CAR-T: phase 1 trial; huCART19-IL18, an IL-18 armored CAR T-cell
81% ORR
51% CR
less toxicity (mostly G1/2)
Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure.”
Title: Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure
Authors: Jakub Svoboda, Daniel J. Landsburg, James Gerson, Sunita D. Nasta, Stefan K. Barta, Elise A. Chong, Michael Cook, Noelle V. Frey, Joanne Shea, Amanda Cervini, Amy Marshall, Megan Four, Megan M. Davis, Julie K. Jadlowsky, Anne Chew, Edward Pequignot, Vanessa Gonzalez, Julia Han Noll, Luca Paruzzo, Juliana Rojas-Levine, Gabriela Plesa, John Scholler, Donald L. Siegel, Bruce L. Levine, David L. Porter, Saba Ghassemi, Marco Ruella, Andrew Rech, Rachel M. Leskowitz, Joseph A. Fraietta, Wei-Ting Hwang, Elizabeth Hexner, Stephen J. Schuster, Carl H. June.
You can read the Full Article in NEJM.
More posts featuring Rahul Kumar.
